Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RenovoRx, Inc. filings document the regulatory record of a life-sciences company commercializing RenovoCath® and developing targeted oncology therapies through its TAMP™ platform. Periodic and current reports disclose operating results, commercialization updates, clinical-trial strategy, and business updates related to the company’s investigational IAG drug-device candidate.
The company’s SEC record includes 8-K filings for financial results, material agreements, equity financings, warrant instruments, and at-the-market offering arrangements. Proxy materials cover annual meeting matters, board governance, executive compensation, and shareholder voting items, while leadership-related filings document officer appointments, compensatory arrangements, and reporting responsibilities.
RenovoRx, Inc. Chief Financial Officer Mark Voll reported an open-market purchase of 25,000 shares of Common Stock at $0.7876 per share on May 19, 2026. Following this purchase, he directly holds 142,380 shares and indirectly holds 97,200 shares through the Voll Family Trust.
A prior grant of 58,953 restricted stock units (RSUs) for his future CFO service remains partly unvested. As of April 30, 2026, 8,823 RSUs had vested and 50,130 RSUs were still unvested.
RenovoRx, Inc. filed an amended annual report to update its risk factors and internal controls disclosure after SEC staff comments. The company clarifies that previously identified material weaknesses in internal control over financial reporting were remediated as of December 31, 2025, and reiterates management’s conclusion that controls were effective at that date. The filing expands discussion of risks tied to its clinical-stage drug‑device candidate IAG, early-stage commercialization of its RenovoCath device, continued operating losses, and the need for additional capital. It also highlights dependence on the Phase III TIGeR‑PaC trial and warns that failure to achieve clinical, regulatory, or commercial milestones could harm its business and stock price.
RenovoRx, Inc. reported first-quarter 2026 results showing rapid early commercialization but continued losses. Revenue from RenovoCath device sales reached $563,000, up from $197,000 a year earlier and described as a 136% quarter-over-quarter increase versus the fourth quarter of 2025. Gross profit was $479,000, but operating expenses of $3.9 million led to a net loss of $3.5 million, or $0.09 per share.
Cash and cash equivalents were $12.4 million as of March 31, 2026, supported by a March 2026 private placement that raised approximately $10.0 million gross. Management believes this cash will fund operations for at least 12 months.
The company is expanding its commercial footprint for RenovoCath, growing from 8 active cancer centers at the end of 2025 to 16 as of May 6, 2026, with 32 more centers in its pipeline. RenovoRx is also nearing full enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with 106 of 114 patients randomized and 74 of 86 required events observed, and continues to anticipate final data in mid to late 2027.
RenovoRx reported record first quarter 2026 results, with revenue of $563,000, up 136% from the fourth quarter of 2025 as adoption of its RenovoCath device and TAMP therapy platform increased across U.S. cancer centers.
Gross margin improved to 85.1%. The company posted a net loss of $3.5 million and non-GAAP net loss of $3.2 million, reflecting higher selling, general and administrative spending to build commercial infrastructure while research and development costs declined. RenovoRx ended the quarter with $12.4 million in cash and completed an oversubscribed private placement raising about $10 million, which management believes will fund operations into at least the second half of 2027.
The commercial footprint expanded to 16 active cancer center customers as of May 6, 2026, with 32 additional centers in the pipeline and a target of 36 active centers by year-end 2026. The Phase III TIGeR-PaC trial for locally advanced pancreatic cancer reached 106 of 114 required randomized patients and 74 of 86 required events, with full enrollment expected by the end of June 2026 and final data anticipated in mid to late 2027. Management reiterated full-year 2026 revenue guidance of $3–$4 million.
RenovoRx, Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 30, 2026 in Mountain View, California. Holders of common stock as of May 11, 2026 may vote on electing six directors, increasing shares under the 2021 equity plan, and ratifying the auditor.
The company proposes adding 2,000,000 shares of common stock, equal to 4.4% of total issued and outstanding shares, to the 2021 Omnibus Equity Incentive Plan. Stockholders will also vote on ratifying Frank, Rimerman + Co. LLP as independent registered public accounting firm for the year ending December 31, 2026.
The proxy describes RenovoRx’s board structure, committee responsibilities, director independence, and compensation. In 2025, CEO Shaun R. Bagai received total compensation of $1,232,317, Executive Chairman and Chief Medical Officer Ramtin Agah, M.D. received $692,246, and Vice President, Controller and Principal Accounting Officer Ronald B. Kocak received $616,696.
RenovoRx, Inc. registers for resale up to 8,438,790 Shares of common stock, 2,200,000 Pre-Funded Warrant Shares, and 5,319,392 Milestone Warrant Shares held by investors from the March 2026 private placement. The company states it is not selling securities here and will not receive proceeds from resales, though it may receive proceeds if holders exercise Milestone Warrants for cash. The Milestone Warrants carry exercise prices of $1.751 for Institutional Investors and $1.9326 for certain insiders and include a beneficial ownership limitation. The registration permits selling stockholders to sell at their discretion via market transactions, block trades, negotiated sales or other methods described under the plan of distribution.
Renovorx, Inc. reports amended beneficial ownership disclosure. Orin Hirschman and affiliated entities jointly report ownership of 4,430,439 shares of Common Stock, representing 9.8%. The filing states this amount excludes 2,082,623 common shares issuable upon exercise of warrants that are not currently exercisable due to a beneficial ownership limitation. The amendment is jointly filed by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr. Hirschman.
RenovoRx, Inc. files a registration statement to permit resale of up to 8,438,790 shares of common stock, 2,200,000 pre-funded-warrant shares, and 5,319,392 milestone-warrant shares by selling stockholders. These securities were issued in a March 2026 private placement and are being registered for resale by the holders.
The company will not receive proceeds from resales, although it may receive up to $9.3 million if all Milestone Warrants are exercised for cash. The common stock trades on Nasdaq under the symbol RNXT; the last reported sale price was $1.02 per share on April 15, 2026.
RenovoRx, Inc. Chief Executive Officer Shaun Bagai received a grant of stock options covering 946,107 shares of common stock at an exercise price of $0.98 per share. The grant was approved by the Compensation Committee.
The options vest over four years at 1/48 per month starting January 1, 2026, becoming fully vested on January 1, 2030, and expiring on April 3, 2036. They are only exercisable when there is an effective registration statement covering the underlying shares.